Knight Therapeutics (OTCMKTS:KHTRF) Trading Up 1% – Here’s Why

Knight Therapeutics Inc. (OTCMKTS:KHTRF) was up 1% during mid-day trading on Thursday . The company traded as high as $6.05 and last traded at $6.05. Approximately 3,000 shares were traded during trading, a decline of 59% from the average daily volume of 7,284 shares. The stock had previously closed at $5.99.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada restated an “outperform” rating on shares of Knight Therapeutics in a research report on Friday, May 8th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy”.

Knight Therapeutics Stock Performance

The stock’s 50-day moving average is $5.70 and its 200-day moving average is $4.85.

About Knight Therapeutics

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.